Abbott reports positive FreeDM2 study results for CGM

Abbott has announced results from the FreeDM2 randomised controlled trial (RCT), indicating that improved glucose outcomes were observed in individuals using the FreeStyle Libre c ...
Drug Delivery Business

Abbott study highlights better glucose outcomes with Libre CGM in type 2 diabetes on basal insulin

Abbott (NYSE:ABT) today announced results from a trial demonstrating better glucose outcomes for users of continuous glucose monitors (CGMs).
PharmiWeb

Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management

At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. those using finger pricking1,2Improvements were participant-led, ...
KPNX-TV Phoenix on MSN

There's a recall on this glucose monitor. Here's what we know

About 3 million ‘Freestyle Libre 3 and 3 plus are being recalled because they can give dangerous false readings.